Immunitybio Inc IBRX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/18/21 EDT
13.41UNCH (UNCH)
Volume
955,215
Close
13.41quote price arrow down-0.49 (-3.53%)
Volume
6,230,243
52 week range
6.03 - 45.42

...

Loading . . .
  • Open13.72
  • Day High13.85
  • Day Low12.71
  • Prev Close13.90
  • 52 Week High45.42
  • 52 Week High Date02/22/21
  • 52 Week Low6.03
  • 52 Week Low Date09/04/20

Key Stats

  • Market Cap5.148B
  • Shares Out383.91M
  • 10 Day Average Volume1.32M
  • Dividend-
  • Dividend Yield-
  • Beta2.13
  • YTD % Change0.6

KEY STATS

  • Open13.72
  • Day High13.85
  • Day Low12.71
  • Prev Close13.90
  • 52 Week High45.42
  • 52 Week High Date02/22/21
  • 52 Week Low6.03
  • 52 Week Low Date09/04/20
  • Market Cap5.148B
  • Shares Out383.91M
  • 10 Day Average Volume1.32M
  • Dividend-
  • Dividend Yield-
  • Beta2.13
  • YTD % Change0.6

RATIOS/PROFITABILITY

  • EPS (TTM)-0.91
  • P/E (TTM)-14.76
  • Fwd P/E (NTM)-17.19
  • EBITDA (MRQ)-138.174M
  • ROE (MRQ)-77.61%
  • Revenue (MRQ)230,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-67,458.95%
  • Debt To Equity (MRQ)-169.91%

EVENTS

  • Earnings Date08/07/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Immunitybio Inc

There is no recent news for this security.

Profile

MORE
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities:...
Patrick Soon-Shiong M.D.
Chairman
Richard Adcock
President
David Sachs
Chief Financial Officer
Address
3530 John Hopkins Ct
San Diego, CA
92121-1121
United States

Top Peers

SYMBOLLASTCHG%CHG
BEAM
Beam Therapeutics Inc
85.00UNCHUNCH
NTLA
Intellia Therapeutics Inc
75.92-0.58-0.76%
TGTX
TG Therapeutics Inc
37.56-0.29-0.77%
RETA
Reata Pharmaceuticals Inc
138.00-1.83-1.31%
VIR
Vir Biotechnology Inc
46.15+2.33+5.32%